R. Koul, S. Mahmood, R. Alvi, M. Salim, H. Chalchal, D. Cross, L. McLean
Background and aim: Anal cancer is a malignant phenomenon which is a distinct entity from the other colorectal malignancies. Local control and sphincter preservation are the two challenges of anal canal cancer treatment that physicians face. Methods and Materials: Population based historical cohort with confirmed histological diagnosis of anal canal or anal margin cancer treated with organ preservation approach such as chemo radiation from 19702006 registered with Saskatchewan Cancer Registry was evaluated. Data was collected on 152 patients; only fifty patients were eligible. Primary end points were colostomy free survival, disease free survival and overall survival. The influences of tumor AJCC stage, nodal stage, age, radiation dose on primary end points were also evaluated. Toxicities scored according to RTOG and late by LENT/SOMA scale. Results: Median age was 58 years (range 31-79 years).Thirty patients (60%) were under 60 years of age and 20 (40%) were above the age of 60 years. Mean follow up was 4.2 years (range 8-21 years). Overall 5 year survival was 53%, 5 year disease specific survival was 67% and 5 year colostomy free survival was 83%. AJCC stage grouping was the only risk factor that showed a statistically significant influence on disease free survival and overall survival. Conclusion: Combined radiochemotherapy for anal cancer is a very effective therapy. Advanced stage at presentation has an adverse effect on overall and disease free survival. However new chemotherapeutic drugs and IMRT based radiation should be thoroughly investigated.
{"title":"A Regional Canadian Cancer Centre Experience with Combined Modality Organ Preservation Treatment in Anal Cancers","authors":"R. Koul, S. Mahmood, R. Alvi, M. Salim, H. Chalchal, D. Cross, L. McLean","doi":"10.5580/ccf","DOIUrl":"https://doi.org/10.5580/ccf","url":null,"abstract":"Background and aim: Anal cancer is a malignant phenomenon which is a distinct entity from the other colorectal malignancies. Local control and sphincter preservation are the two challenges of anal canal cancer treatment that physicians face. Methods and Materials: Population based historical cohort with confirmed histological diagnosis of anal canal or anal margin cancer treated with organ preservation approach such as chemo radiation from 19702006 registered with Saskatchewan Cancer Registry was evaluated. Data was collected on 152 patients; only fifty patients were eligible. Primary end points were colostomy free survival, disease free survival and overall survival. The influences of tumor AJCC stage, nodal stage, age, radiation dose on primary end points were also evaluated. Toxicities scored according to RTOG and late by LENT/SOMA scale. Results: Median age was 58 years (range 31-79 years).Thirty patients (60%) were under 60 years of age and 20 (40%) were above the age of 60 years. Mean follow up was 4.2 years (range 8-21 years). Overall 5 year survival was 53%, 5 year disease specific survival was 67% and 5 year colostomy free survival was 83%. AJCC stage grouping was the only risk factor that showed a statistically significant influence on disease free survival and overall survival. Conclusion: Combined radiochemotherapy for anal cancer is a very effective therapy. Advanced stage at presentation has an adverse effect on overall and disease free survival. However new chemotherapeutic drugs and IMRT based radiation should be thoroughly investigated.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2009-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91231813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Medical informatics is a basic biomedical science that has a wide variety of application areas which involve improvements in the management of any information relevant to patient care and community health. Oncoinformatics is an application science under this broad field. This area applies informatics, internet, and interactive technologies with the aim of improving the standards of care for the cancer patient. The rapid growth of the World Wide Web as a tool for global connectivity has impacted the way in which health-related information is distributed and accessed over the internet. Many people frequently use the internet for the searching of drug and other health-related information. Oncoinformatics has enabled the collation of a huge amount of information in the area of oncology. Several oncology-specific databases and blogs that are clinically relevant are described in this paper. The impact of informatics technologies and cybermedicine in oncology is also discussed.
{"title":"Oncoinformatics for the healthcare professional: oncology databases and blogs","authors":"K. Yap, Yu Zong Chen, W. Chui, A. Chan","doi":"10.5580/B6B","DOIUrl":"https://doi.org/10.5580/B6B","url":null,"abstract":"Medical informatics is a basic biomedical science that has a wide variety of application areas which involve improvements in the management of any information relevant to patient care and community health. Oncoinformatics is an application science under this broad field. This area applies informatics, internet, and interactive technologies with the aim of improving the standards of care for the cancer patient. The rapid growth of the World Wide Web as a tool for global connectivity has impacted the way in which health-related information is distributed and accessed over the internet. Many people frequently use the internet for the searching of drug and other health-related information. Oncoinformatics has enabled the collation of a huge amount of information in the area of oncology. Several oncology-specific databases and blogs that are clinically relevant are described in this paper. The impact of informatics technologies and cybermedicine in oncology is also discussed.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"79487509","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Salivary duct carcinoma is an uncommon malignant tumor, characterized by aggressive behavior and poor prognosis. It accounts for approximately 1–3% of all malignant salivary gland tumors (2), and it is found mainly in the parotid gland, followed by the other major salivary glands (2). Histologically, salivary duct carcinoma resembles ductal carcinoma of the breast (3). Immunohistochemically, the tumor cells are positive for keratin and epithelial membrane antigen. Stains for gross cystic disease fluid protein-15 (GCDFP-15) and androgen receptor are frequently positive, but only rare expression of estrogen and progesterone receptors has been described (3). Metastases are a common feature in the evolution of parotid gland cancer. Gastrointestinal metastases, however, and especially appendicular ones, are very rare. The intrinsic nature of malignant metastases in the appendix leads to a late presentation of appendicitis with a high incidence of perforation, associated with an increased mortality and morbidity (1). We describe the case of a patient presenting as an acute abdomen because of metastatic involvement with perforation of the vermiform appendix from a salivary duct carcinoma of the parotid gland treated with paclitaxel.
{"title":"Metastatic involvement and perforation of the appendix in a patient with parotid gland tumor treated with paclitaxel","authors":"T. Grenader, Anthony Goldberg, C. Reinus","doi":"10.5580/1bd8","DOIUrl":"https://doi.org/10.5580/1bd8","url":null,"abstract":"Salivary duct carcinoma is an uncommon malignant tumor, characterized by aggressive behavior and poor prognosis. It accounts for approximately 1–3% of all malignant salivary gland tumors (2), and it is found mainly in the parotid gland, followed by the other major salivary glands (2). Histologically, salivary duct carcinoma resembles ductal carcinoma of the breast (3). Immunohistochemically, the tumor cells are positive for keratin and epithelial membrane antigen. Stains for gross cystic disease fluid protein-15 (GCDFP-15) and androgen receptor are frequently positive, but only rare expression of estrogen and progesterone receptors has been described (3). Metastases are a common feature in the evolution of parotid gland cancer. Gastrointestinal metastases, however, and especially appendicular ones, are very rare. The intrinsic nature of malignant metastases in the appendix leads to a late presentation of appendicitis with a high incidence of perforation, associated with an increased mortality and morbidity (1). We describe the case of a patient presenting as an acute abdomen because of metastatic involvement with perforation of the vermiform appendix from a salivary duct carcinoma of the parotid gland treated with paclitaxel.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87225463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nermina Kantardži, Velda Smajlbegovi, N. Kazic, A. Cardzic
Background: During radiotherapy or chemotherapy of head and neck tumours patients commonly suffer from oral mucositis. Symptoms of oral mucositis are pain; discomfort or inability to tolerate food and fluid. Mucositis can be severe and limit the patient’s ability to tolerate chemotherapy or radiotherapy, cause delay and limit the effectiveness of cancer therapy. Aim: To examine effectiveness of gelclair oral gel in the treatment of oral mucisitis in patients with head and neck tumours during radiotherapy or/and chemotherapy. Material and method: This is nonrandomized, prospective study. We included 15 patients treated with radiotherapy and/or chemotherapy and proven head and neck tumours. During their oncology therapy they were treated with gelclear oral gel and checked every day for severity of their symptoms. Results: In the 13 patients significant improvement in the management of pain was observed, and 11 patients had improvement in food and fluid intakes. There were no delays in treatment, caused by severity of oral mucositis. Conclusion: Gelclear oral gel is safe and efficient agent in the treatment of oral mucositis, one of most common complication of radiotherapy and/or chemotherapy in patients with head and neck tumours. This study was supported by Pharma Swiss – department Sarajevo, Bosnia and Herzegovina. INTRODUCTION Malignant head and neck tumours represent about 4% of all malignancies. Squamous cancers of the upper aero digestive tract constitute approximately 6% of new cancer cases in men and 2% in female at all sites, except the salivary glands; there is a significant preponderance of cases in men1. It is most common between 45 to 70 years2. In the time of diagnosis about 70 % of patients are in III or IV stage of disease3. Treatment options include surgery, radiotherapy and chemotherapy, before, during or after radiotherapy. If the patients are treated with radio and/or chemotherapy one of the most common side effects is oral mucositis. It occurs in 20-40% of patients treated with chemotherapy alone and up to 50% of patients receiving combination radiation and chemotherapy, especially those with head and neck tumors. Main symptoms of oral mucositis are: erythema, taste loss, pain, and a sore or dry mouth, swallowing and eating difficulty. Tooth and gum disease further complicate the problem. Reduction of caloric intake can lead to weight loss, loss in muscle mass strength and other complications, including a decrease in immunity. Patients with damaged oral mucosa and reduced immunity are prone to opportunistic mouth infections. The potential impact of morbidity and mortality with oral mucositis should not be underestimated and requires active treatment. The consequences of mucositis can be mild requiring little intervention to severe that may result in fatal complications. If oral mucisitis is not treated it can cause delays in chemotherapy and/or radiotherapy treatment, or even stopping of specific oncology treatments and comprom
{"title":"Efficacy of Gelclair oral gel in the treatment of oral mucositis in patients with head and neck tumours treated with chemotherapy and /or radiotherapy","authors":"Nermina Kantardži, Velda Smajlbegovi, N. Kazic, A. Cardzic","doi":"10.5580/667","DOIUrl":"https://doi.org/10.5580/667","url":null,"abstract":"Background: During radiotherapy or chemotherapy of head and neck tumours patients commonly suffer from oral mucositis. Symptoms of oral mucositis are pain; discomfort or inability to tolerate food and fluid. Mucositis can be severe and limit the patient’s ability to tolerate chemotherapy or radiotherapy, cause delay and limit the effectiveness of cancer therapy. Aim: To examine effectiveness of gelclair oral gel in the treatment of oral mucisitis in patients with head and neck tumours during radiotherapy or/and chemotherapy. Material and method: This is nonrandomized, prospective study. We included 15 patients treated with radiotherapy and/or chemotherapy and proven head and neck tumours. During their oncology therapy they were treated with gelclear oral gel and checked every day for severity of their symptoms. Results: In the 13 patients significant improvement in the management of pain was observed, and 11 patients had improvement in food and fluid intakes. There were no delays in treatment, caused by severity of oral mucositis. Conclusion: Gelclear oral gel is safe and efficient agent in the treatment of oral mucositis, one of most common complication of radiotherapy and/or chemotherapy in patients with head and neck tumours. This study was supported by Pharma Swiss – department Sarajevo, Bosnia and Herzegovina. INTRODUCTION Malignant head and neck tumours represent about 4% of all malignancies. Squamous cancers of the upper aero digestive tract constitute approximately 6% of new cancer cases in men and 2% in female at all sites, except the salivary glands; there is a significant preponderance of cases in men1. It is most common between 45 to 70 years2. In the time of diagnosis about 70 % of patients are in III or IV stage of disease3. Treatment options include surgery, radiotherapy and chemotherapy, before, during or after radiotherapy. If the patients are treated with radio and/or chemotherapy one of the most common side effects is oral mucositis. It occurs in 20-40% of patients treated with chemotherapy alone and up to 50% of patients receiving combination radiation and chemotherapy, especially those with head and neck tumors. Main symptoms of oral mucositis are: erythema, taste loss, pain, and a sore or dry mouth, swallowing and eating difficulty. Tooth and gum disease further complicate the problem. Reduction of caloric intake can lead to weight loss, loss in muscle mass strength and other complications, including a decrease in immunity. Patients with damaged oral mucosa and reduced immunity are prone to opportunistic mouth infections. The potential impact of morbidity and mortality with oral mucositis should not be underestimated and requires active treatment. The consequences of mucositis can be mild requiring little intervention to severe that may result in fatal complications. If oral mucisitis is not treated it can cause delays in chemotherapy and/or radiotherapy treatment, or even stopping of specific oncology treatments and comprom","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87975623","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. vaginalis was suggested to be an associated factor in carcenogenesis. We have studied 41 breast disease (31 breast cancer and 10 fibrosing adenomatosis) patients for the presence of G. vaginalis by PCR in tumor, blood and saliva. G. vaginalis was detected in 46% of saliva samples, 44% of blood samples, and 56% of tumor; in 85% cases at least one of patient’s samples was found to be G. vaginalis positive. For the first time, a relationship between G. vaginalis and breast disease was shown
{"title":"Gardnerella vaginalis and breast cancer","authors":"L. Tumanova, V. Mitin, N. Godoroja, N. Botnariuc","doi":"10.5580/219c","DOIUrl":"https://doi.org/10.5580/219c","url":null,"abstract":"G. vaginalis was suggested to be an associated factor in carcenogenesis. We have studied 41 breast disease (31 breast cancer and 10 fibrosing adenomatosis) patients for the presence of G. vaginalis by PCR in tumor, blood and saliva. G. vaginalis was detected in 46% of saliva samples, 44% of blood samples, and 56% of tumor; in 85% cases at least one of patient’s samples was found to be G. vaginalis positive. For the first time, a relationship between G. vaginalis and breast disease was shown","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"76147260","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
It is a mantra, a dogma, a belief system. It has merit. It has saved many lives. It is almost 50 years now since Bernie Fisher first noted the high relapse rate in patients with breast cancer who had been “cured” by surgery. He realized more needed to be done. He set up systemic studies, went step by step and established a new approach to the understanding and “early” breast cancer. Seventy years before that, Halstead had developed what was thought to be the best approach for the treatment of breast cancer. Based on the best thinking and understanding at that time, he developed a surgical method that helped many but also reduced the quality of life of many others without giving them any benefit – that is what we found out later.
{"title":"Adjuvant Therapy with Curative Intent: Is That Really So?","authors":"A. Mangalik","doi":"10.5580/12da","DOIUrl":"https://doi.org/10.5580/12da","url":null,"abstract":"It is a mantra, a dogma, a belief system. It has merit. It has saved many lives. It is almost 50 years now since Bernie Fisher first noted the high relapse rate in patients with breast cancer who had been “cured” by surgery. He realized more needed to be done. He set up systemic studies, went step by step and established a new approach to the understanding and “early” breast cancer. Seventy years before that, Halstead had developed what was thought to be the best approach for the treatment of breast cancer. Based on the best thinking and understanding at that time, he developed a surgical method that helped many but also reduced the quality of life of many others without giving them any benefit – that is what we found out later.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"74091237","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
G. Karunanithi, P. Sethi, K. S. Reddy, S. Vivekanandam
Radiation-induced sarcomas are uncommon potential late sequelae of radiation therapy. These tumors are aggressive, occurring in bones or soft tissues in an irradiated area after a latent period of five or more years following radiotherapy. We report a case of radiation-induced osteosarcoma involving the pelvic girdle with latency period of 11 years following whole pelvis radiation treatment for carcinoma cervix.
{"title":"Radiation Induced Sarcoma of Pelvis","authors":"G. Karunanithi, P. Sethi, K. S. Reddy, S. Vivekanandam","doi":"10.5580/2299","DOIUrl":"https://doi.org/10.5580/2299","url":null,"abstract":"Radiation-induced sarcomas are uncommon potential late sequelae of radiation therapy. These tumors are aggressive, occurring in bones or soft tissues in an irradiated area after a latent period of five or more years following radiotherapy. We report a case of radiation-induced osteosarcoma involving the pelvic girdle with latency period of 11 years following whole pelvis radiation treatment for carcinoma cervix.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"73510939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
R. Seshadri, Ritesh Tapkire, U. Majhi, Selvaluxmy Ganesharajah
Abstract Metastasis from carcinoma of the uterine cervix to the gastrointestinal tract is uncommonand is usually associated with a poor prognosis. We report a case of a 50-year-old lady treated byconcurrent chemoradiation for stage III B carcinoma of the uterine cervix. One and a half yearslater, she developed a metastatic growth in the transverse colon which was resected. She isdisease free ten months after surgery. The colon is an unusual site of metastasis from carcinomacervix, and colonic metastasis from carcinoma cervix has to be differentiated from a primarysquamous cell carcinoma of the colon. Palliative resection of colonic metastasis may preventfuture intestinal obstruction.
{"title":"Colonic metastasis from primary squamous cell carcinoma of the cervix","authors":"R. Seshadri, Ritesh Tapkire, U. Majhi, Selvaluxmy Ganesharajah","doi":"10.5580/739","DOIUrl":"https://doi.org/10.5580/739","url":null,"abstract":"Abstract Metastasis from carcinoma of the uterine cervix to the gastrointestinal tract is uncommonand is usually associated with a poor prognosis. We report a case of a 50-year-old lady treated byconcurrent chemoradiation for stage III B carcinoma of the uterine cervix. One and a half yearslater, she developed a metastatic growth in the transverse colon which was resected. She isdisease free ten months after surgery. The colon is an unusual site of metastasis from carcinomacervix, and colonic metastasis from carcinoma cervix has to be differentiated from a primarysquamous cell carcinoma of the colon. Palliative resection of colonic metastasis may preventfuture intestinal obstruction.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"77205710","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Appendiceal tumors are rare neoplasms occurring in approximately 0.1% of appendectomy specimens1. The majority present as acute appendicitis and are treated by simple appendectomy. Although controversial, in the setting of peritoneal carcinomatosis discovered at the time of appendectomy, cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) may represent potential therapeutic options. However, debate exists with regard to patient selection, quality of life and procedureassociated morbidity, what constitutes effective cytoreduction, and whether cytoreduction alone offers a survival benefit in the absence of intraperitoneal chemotherapy. This report describes a rare case of a perforated appendiceal adenocarcinoma arising after bone marrow transplantation for non-Hodgkin lymphoma. The occurrence of peritoneal carcinomatosis in this setting has not previously been reported, but exemplifies the importance of an individualized approach to therapy based on a patient’s presentation.
{"title":"Appendiceal Adenocarcinoma Arising after Bone Marrow Transplantation for Non-Hodgkin Lymphoma: An Unusual Treatment Dilemma","authors":"J. Schwartz, B. Woods, L. Emerson, R. Andtbacka","doi":"10.5580/48a","DOIUrl":"https://doi.org/10.5580/48a","url":null,"abstract":"Appendiceal tumors are rare neoplasms occurring in approximately 0.1% of appendectomy specimens1. The majority present as acute appendicitis and are treated by simple appendectomy. Although controversial, in the setting of peritoneal carcinomatosis discovered at the time of appendectomy, cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) may represent potential therapeutic options. However, debate exists with regard to patient selection, quality of life and procedureassociated morbidity, what constitutes effective cytoreduction, and whether cytoreduction alone offers a survival benefit in the absence of intraperitoneal chemotherapy. This report describes a rare case of a perforated appendiceal adenocarcinoma arising after bone marrow transplantation for non-Hodgkin lymphoma. The occurrence of peritoneal carcinomatosis in this setting has not previously been reported, but exemplifies the importance of an individualized approach to therapy based on a patient’s presentation.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82946688","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pharmacokinetics of adriamycin in the rat testis, heart and plasma was Investigated using male Wister rats. The control group received 0. 9%saline Given I.V. One group of adriamycin treated rats received 20mg/kg adriamycin administered intravenously. The Second group received1mg/kg adriamycin also given I.V. Thereafter, the animals weresacrificed 1,3,12 and 24 hours and the testes, and hearts were removed.The plasma was recovered from the blood. Using fluorimetric method, the amount of adriamycin in the tissues and plasma was quantitated. The Half life of the drug in the tissues and plasma was calculated from the Graph of log adriamycin concentration (ug/g) vs. time. The pattern of distribution in the heart and plasma at the two doses used in the pharmacokinetic studies revealed an exponential fall in drug concentration with time. In the testis on the other hand, after the initial drop on the level of the drug in this organ, the level of the drug was elevated with time. This ability of the testis to accumulate adriamycin renders it highly susceptible to the lethal effects of adriamycin And thus accounts for the observed drug induced testicular toxicity.
{"title":"Pharmacokinetics Of Adriamycin After Intravenous Administration In Rat.","authors":"R. Nwankwoala, O. Georgewill, U. Georgewill","doi":"10.5580/1dc4","DOIUrl":"https://doi.org/10.5580/1dc4","url":null,"abstract":"Pharmacokinetics of adriamycin in the rat testis, heart and plasma was Investigated using male Wister rats. The control group received 0. 9%saline Given I.V. One group of adriamycin treated rats received 20mg/kg adriamycin administered intravenously. The Second group received1mg/kg adriamycin also given I.V. Thereafter, the animals weresacrificed 1,3,12 and 24 hours and the testes, and hearts were removed.The plasma was recovered from the blood. Using fluorimetric method, the amount of adriamycin in the tissues and plasma was quantitated. The Half life of the drug in the tissues and plasma was calculated from the Graph of log adriamycin concentration (ug/g) vs. time. The pattern of distribution in the heart and plasma at the two doses used in the pharmacokinetic studies revealed an exponential fall in drug concentration with time. In the testis on the other hand, after the initial drop on the level of the drug in this organ, the level of the drug was elevated with time. This ability of the testis to accumulate adriamycin renders it highly susceptible to the lethal effects of adriamycin And thus accounts for the observed drug induced testicular toxicity.","PeriodicalId":22534,"journal":{"name":"The Internet Journal of Oncology","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2008-12-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"82088074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：